All Stories

  1. Long-term maintenance of remission with spacing of rituximab infusions based on the individualised patient risk profile in ANCA-associated vasculitis: a pilot study

    Article • RMD Open, June 2025, BMJ

    Sara Monti

  2. Correspondence on ‘EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update’ by Hellmich et al

    Article • Annals of the Rheumatic Diseases, October 2024, Elsevier

    Sara Monti

  3. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica

    Article • Annals of the Rheumatic Diseases, March 2024, Elsevier

    Sara Monti

  4. Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study

    Article • Arthritis & Rheumatology, February 2024, Wiley

    Sara Monti

  5. Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire

    Article • Rheumatology Advances in Practice, December 2023, Oxford University Press (OUP)

    Sara Monti

  6. Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients

    Article • Annals of the Rheumatic Diseases, August 2023, Elsevier

    Sara Monti

  7. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis

    Article • RMD Open, July 2023, BMJ

    Sara Monti

  8. Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study

    Article • Rheumatology, June 2023, Oxford University Press (OUP)

    Sara Monti

  9. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV

    Article • RMD Open, June 2023, BMJ

    Sara Monti

  10. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica

    Article • Rheumatology, May 2023, Oxford University Press (OUP)

    Sara Monti

  11. The provisional OMERACT ultrasonography score for giant cell arteritis

    Article • Annals of the Rheumatic Diseases, April 2023, Elsevier

    Sara Monti

  12. Remission and Low Disease Activity in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual

    Article • Arthritis Care & Research, December 2022, Wiley

    Sara Monti

  13. Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment

    Article • Seminars in Arthritis and Rheumatism, October 2022, Elsevier

    Sara Monti

  14. Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis

    Article • Rheumatology, June 2022, Oxford University Press (OUP)

    Sara Monti

  15. Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review

    Article • Rheumatology, March 2022, Oxford University Press (OUP)

    Sara Monti

  16. A New Era for the Early and Non-Invasive Diagnosis of Giant Cell Arteritis: The Use of Fast-Track Ultrasound in Clinical Practice

    Article • Applied Sciences, February 2022, MDPI AG

    Sara Monti

  17. Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis

    Article • Annals of the Rheumatic Diseases, November 2021, Elsevier

    Sara Monti

  18. Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis

    Article • Rheumatology, October 2021, Oxford University Press (OUP)

    Sara Monti

  19. Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’

    Article • Annals of the Rheumatic Diseases, October 2021, Elsevier

    Sara Monti

  20. Response to: ‘Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler et al

    Article • Annals of the Rheumatic Diseases, June 2021, Elsevier

    Sara Monti

  21. Striking abdominal aortic stenosis revealing Takayasu’s arteritis

    Article • European Heart Journal - Cardiovascular Imaging, May 2021, Oxford University Press (OUP)

    Sara Monti

  22. Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al

    Article • Annals of the Rheumatic Diseases, May 2021, Elsevier

    Sara Monti

  23. Novel Therapies for ANCA-associated Vasculitis

    Article • Current Rheumatology Reports, April 2021, Springer Science + Business Media

    Sara Monti

  24. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis

    Article • Rheumatology, March 2021, Oxford University Press (OUP)

    annalisa de silvestri, Sara Monti

  25. Candidate rheumatologic treatments for COVID-19. Response to: ‘COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak

    Article • Annals of the Rheumatic Diseases, March 2021, Elsevier

    Sara Monti

  26. Comorbidities and rheumatological diseases at the time of COVID-19. Response to: ‘Rheumatic diseases in intensive care unit patients with COVID-19‘ by Moiseev et al

    Article • Annals of the Rheumatic Diseases, February 2021, Elsevier

    Sara Monti

  27. Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: ‘Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)‘ by Giollo et al

    Article • Annals of the Rheumatic Diseases, February 2021, Elsevier

    Sara Monti

  28. Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: ‘COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs...

    Article • Annals of the Rheumatic Diseases, February 2021, Elsevier

    Sara Monti

  29. Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: ‘Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia’ by Guilpa...

    Article • Annals of the Rheumatic Diseases, January 2021, Elsevier

    Sara Monti

  30. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India’ by Gupta et al and ‘Antirheumat...

    Article • Annals of the Rheumatic Diseases, January 2021, Elsevier

    Sara Monti

  31. Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis

    Article • Annals of the Rheumatic Diseases, December 2020, Elsevier

    Sara Monti

  32. Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis

    Article • Seminars in Arthritis and Rheumatism, December 2020, Elsevier

    Sara Monti

  33. Incidence of COVID‐19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?

    Article • Arthritis & Rheumatology, September 2020, Wiley

    Sara Monti

  34. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis

    Article • Rheumatology, July 2020, Oxford University Press (OUP)

    Sara Monti

  35. Lumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case

    Article • Rheumatology, June 2020, Oxford University Press (OUP)

    Sara Monti

  36. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment...

    Article • Annals of the Rheumatic Diseases, June 2020, Elsevier

    Sara Monti

  37. Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes

    Article • Rheumatology, May 2020, Oxford University Press (OUP)

    Sara Monti

  38. Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis

    Article • Rheumatology, May 2020, Oxford University Press (OUP)

    Sara Monti

  39. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

    Article • Annals of the Rheumatic Diseases, May 2020, Elsevier

    Sara Monti

  40. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis

    Article • Rheumatology, April 2020, Oxford University Press (OUP)

    Sara Monti

  41. Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors

    Article • Journal of Autoimmunity, March 2020, Elsevier

    Sara Monti

  42. The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis

    Article • Rheumatology, December 2019, Oxford University Press (OUP)

    Sara Monti

  43. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis

    Article • RMD Open, September 2019, BMJ

    Sara Monti

  44. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis

    Article • RMD Open, September 2019, BMJ

    Sara Monti

  45. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis

    Article • Annals of the Rheumatic Diseases, July 2019, BMJ

    Sara Monti

  46. THU0290 DISEASE AND TREATMENT-RELATED MORBIDITY IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS

    Article • June 2019, BMJ

    Sara Monti

  47. FRI0287 EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS

    Article • June 2019, BMJ

    Sara Monti

  48. THU0286 MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS

    Article • June 2019, BMJ

    Sara Monti

  49. SAT0239 PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG–STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS

    Article • June 2019, BMJ

    Sara Monti

  50. FRI0284 RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS

    Article • June 2019, BMJ

    Sara Monti

  51. OP0142 THE IMPACT OF DISEASE EXTENT AND SEVERITY DETECTED BY QUANTITATIVE ULTRASOUND ANALYSIS IN THE DIAGNOSIS AND OUTCOME OF GIANT CELL ARTERITIS: RESULTS FROM THE TEMPORAL ARTERYBIOPSY VERSUS ULTRASOUND (TABUL) STUDY AND VALIDATION IN AN INDEPENDENT ...

    Article • Annals of the Rheumatic Diseases, June 2019, Elsevier

    Sara Monti

  52. SAT0667 TREATMENT RESPONSE CRITERIA FOR ANCA-ASSOCIATED VASCULITIS: RESULTS OF A SCOPING REVIEW

    Article • Annals of the Rheumatic Diseases, June 2019, Elsevier

    Sara Monti

  53. IgG4-related diseases: state of the art on clinical practice guidelines

    Article • RMD Open, January 2019, BMJ

    Sara Monti

  54. Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management

    Article • Drugs & Aging, November 2018, Springer Science + Business Media

    Sara Monti

  55. 20 years of experience with tumour necrosis factor inhibitors: what have we learned?

    Article • Rheumatology, October 2018, Oxford University Press (OUP)

    Sara Monti

  56. Randomized controlled trials and real-world data: differences and similarities to untangle literature data

    Article • Rheumatology, October 2018, Oxford University Press (OUP)

    Sara Monti

  57. The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature

    Article • Rheumatology International, August 2018, Springer Science + Business Media

    Sara Monti

  58. OP0238 Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. analysis from the dcvas study

    Article • June 2018, BMJ

    Sara Monti

  59. SAT0327 Baseline characteristics and reasons for apremilast prescription in a large italian cohort of psoriatic arthritis patients

    Article • June 2018, BMJ

    Sara Monti

  60. FRI0504 Diffuse alveolar haemorrhagein anca-associated vasculitis: can we predict outcome? an italian multicentre retrospective long-term study of 102 patients

    Article • June 2018, BMJ

    Sara Monti

  61. FRI0114 Efficacy and retention rate of certolizumab pegol in rheumatoid arthritis: data from a large real-life multicentre retrospective cohort

    Article • June 2018, BMJ

    Sara Monti

  62. AB0700 Is it feasible to withdraw immunosuppressive treatment in real-life patients with anca-associated vasculitis?

    Article • June 2018, BMJ

    Sara Monti

  63. OP0333 Survival in anca associated vasculitides: a retrospective multicentric analysis in northern italy

    Article • June 2018, BMJ

    Sara Monti

  64. Clinical spectrum of anti-Jo-1-associated disease

    Article • Current Opinion in Rheumatology, November 2017, Wolters Kluwer Health

    Sara Monti

  65. The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice

    Article • Rheumatology, October 2017, Oxford University Press (OUP)

    Sara Monti

  66. How I treat idiopathic patients with inflammatory myopathies in the clinical practice

    Article • Autoimmunity Reviews, October 2017, Elsevier

    Sara Monti

  67. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors

    Article • Modern Rheumatology, September 2017, Taylor & Francis

    Sara Monti

  68. THU0297 A novel ultrasound scoring system for giant cell arteritis

    Article • June 2017, BMJ

    Sara Monti

  69. FRI0337 Anca pattern in granulomatosis with polyangitis and micropolyangitis. a retrospective analysis on a multicentric inception cohort

    Article • June 2017, BMJ

    Sara Monti

  70. THU0302 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the tabul study (temporal artery biopsy vs ultrasound in diagnosis of giant cell arteritis)

    Article • June 2017, BMJ

    Sara Monti

  71. FRI0312 The frequency and severity of patient-reported symptoms in giant cell arteritis

    Article • June 2017, BMJ

    Sara Monti

  72. AB0589 The role of anca specificity in the clinical manifestations at disease onset: comparison between patients with granulomatosis with polyangiitis and microscopic polyangiitis

    Article • June 2017, BMJ

    Sara Monti

  73. THU0296 The role of ultrasound in the management of giant cell arteritis (GCA) in routine clinical practice

    Article • June 2017, BMJ

    Sara Monti

  74. ANCA-associated vasculitis in childhood: recent advances

    Article • Italian Journal of Pediatrics, May 2017, Springer Science + Business Media

    Sara Monti

  75. The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist

    Article • Rheumatology, April 2017, Oxford University Press (OUP)

    Sara Monti

  76. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry

    Article • Clinical Rheumatology, January 2017, Springer Science + Business Media

    Sara Monti

  77. AB0569 Does The Age at Disease Onset Influence The Clinical Presentation and Long-Term Outcome of Anca-Associated Vasculitides? Results from A Single-Centre Cohort: Table 1.

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  78. FRI0232 Factors Influencing The Choice of First and Second Line Biologic Therapy for The Treatment of Rheumatoid Arthritis: Real Life Data from The Italian Lorhen Registry

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  79. AB0226 One Year Experience of A Bdmard Spacing Protocol in Real Life Rheumatoid Arthritis Patients

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  80. FRI0174 Two-Year Retention Rate of Subcutaneous Anti-Tumor Necrosis Factor Agents for Rheumatoid Arthritis: A Retrospective Analysis of The Lorhen Registry

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  81. Chronic pain: the burden of disease and treatment innovations

    Article • Reumatismo, October 2015, PAGEPress Publications

    Sara Monti

  82. Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients

    Article • The Journal of Rheumatology, October 2015, The Journal of Rheumatology

    Sara Monti

  83. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage

    Article • RMD Open, August 2015, BMJ

    Sara Monti

  84. AB0401 Anxiety and Depression in Patients with Rheumatoid Arthritis Treated with Biological Drugs: Prevalence and Relationship with Disease Activity

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  85. AB0426 Biologic Spacing in Rheumatoid Arthritis Patients in Persistent Disease Activity Control: A Real Life Experience

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  86. FRI0182 Comorbidities Influence the Choice of the Biologic Agent: Real Life Data from the Lorhen Registry

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  87. FRI0278 Life-Threatening Onset of Systemic Vasculitis Requiring Intensive Care Unit Admission: A Case Series

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  88. AB0664 Off Label Biologic Therapy in a Cohort of Patients with Behçet Disease

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  89. AB0788 Treating Axial-Spa to Target: Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Anti-TNFα Agents

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  90. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Sara Monti

  91. Perivascular fibrosis and IgG4-related disease: a case report

    Article • Reumatismo, November 2014, PAGEPress Publications

    Sara Monti

  92. Pneumocephalus due to granulomatosis with polyangiitis

    Article • Rheumatology, September 2014, Oxford University Press (OUP)

    Sara Monti

  93. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis

    Article • Journal of Nephrology, September 2014, Springer Science + Business Media

    Sara Monti

  94. Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-treated patients

    Article • Clinical Rheumatology, May 2014, Springer Science + Business Media

    Marco Quaglia, Sara Monti

  95. Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature

    Article • Clinical Rheumatology, April 2014, Springer Science + Business Media

    Sara Monti

  96. The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis

    Article • BioMed Research International, January 2013, Hindawi Publishing Corporation

    Sara Monti